Satsuma Pharmaceuticals, Inc. (STSA) has an overall financial health rating of B- with a composite score of 0 out of 5.
This suggests the company faces some financial challenges worth monitoring. Rating as of 2023-06-07.
| Date | Rating | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2023-06-07 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-06-06 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-06-05 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-06-02 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-06-01 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-05-31 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-05-30 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-05-26 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-05-25 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-05-24 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-05-23 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-05-22 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 |
